## **ICMJE DISCLOSURE FORM**

Da	te:2021/11/17				
Yo	ur Name:Min Fu				
aı		injury via blocking th	bit the excessive proliferation of synovial cells, ne NF-κB/STAT3 pathway		
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply muscript only.	manuscript. "Related" mee affected by the content necessarily indicate a bias it is preferable that you d to the author's relationsh ivities/interests should be ension, you should declare	dips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive		
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initia	al planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone			
		Time frame: pas	t 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone			
3	Royalties or licenses	XNone			
4	Consulting fees	<b>X</b> None			

5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
-	6 16 11 11			
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
_				
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	•	••		
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	<b>X</b> None		
	Stock of Stock options	XNone		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	<b>X</b> None		
	services			
13	Other financial or non-	<b>X</b> None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
None.				

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## **ICMJE DISCLOSURE FORM**

Da	te:2021/11/17	· —————————————			
	Your Name:Xiaoxiao Sang				
ar	Manuscript Title:Total glucosides of peony inhibit the excessive proliferation of synovial cells, and ameliorate cartilage injury via blocking the NF-κB/STAT3 pathway				
rela par to	ated to the content of your ties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.		
	e following questions apply nuscript only.	to the author's relationsh	nips/activities/interests as they relate to the current		
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.					
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initi	al planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone			
		Time frame: pas	st 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone			
3	Royalties or licenses	X None			

Consulting fees

X\_\_None

4

5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
-	6 16 11 11			
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
_				
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	•	••		
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	<b>X</b> None		
	Stock of Stock options	XNone		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	<b>X</b> None		
	services			
13	Other financial or non-	<b>X</b> None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
None.				

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## **ICMJE DISCLOSURE FORM**

Da	te:2021/11/17		
	ur Name:Hongxia		
aı		injury via blocking tl	bit the excessive proliferation of synovial cells, he NF-κB/STAT3 pathway
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
	e following questions apply inuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>
to		ension, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive on the manuscript.
	item #1 below, report all su e time frame for disclosure	· ·	ed in this manuscript without time limit. For all other items
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time from	at 26 months
2	Grants or contracts from	Time frame: pas X None	St 56 months
_	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	

Consulting fees

X\_\_None

4

5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
-	6 16 11 11			
7	Support for attending	XNone		
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
_				
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	•	••		
10	Leadership or fiduciary role	XNone		
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	<b>X</b> None		
	Stock of Stock options	XNone		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	<b>X</b> None		
	services			
13	Other financial or non-	<b>X</b> None		
	financial interests			
Ple	Please summarize the above conflict of interest in the following box:			
None.				

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.